Moffitt Presentation at SITC 2021

Friday, November 12 

Time Type Title No. Author
7 a.m. to 8 p.m. Poster Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known 87 Ahmad A. Tarhini, MD, PhD, MS
7 a.m. to 8 p.m. Poster 4-1BB and optimized CD28 co-stimulation enhances function of human mono- and bi-specific third-generation CAR T cells 105

Emiliano Roselli, PhD

7 a.m. to 8 p.m. Poster CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity 179 Jonathan A. Hensel, PhD
7 a.m. to 8 p.m. Poster Stimulation of tumor infiltrating B-cells improves ex-vivo TIL expansion for melanoma immunotherapy 195 Renata AM. Rossetti, PhD
7 a.m. to 8 p.m. Poster Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL) 385 MacLean Hall, BS


Saturday, November 13

Time Type Title No. Author
7 a.m. to 8 p.m. Poster An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy 384

MacLean Hall, BS

7 a.m. to 8 p.m. Poster In vivo demethylation-mediated reversal of tumor cell-intrinsic cGAS silencing improves the efficacy of STING agonist therapy 760 Rana Falahat, PhD
12:15 p.m. Oral CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) 955 Roger Li, MD